1245506-61-9

Basic information

• Product Name: 2-Chloro-5-methoxy-4-methylpyrimidine
• Synonyms: 2-Chloro-5-methoxy-4-methylpyrimidine
• CAS NO: 1245506-61-9
• Molecular Formula: C₆H₇ClN₂O
• Molecular Weight: 158.58558
• Mol File: 1245506-61-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 255.6±20.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.76±0.29(Predicted)
• CAS DataBase Reference: 2-Chloro-5-methoxy-4-methylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-methoxy-4-methylpyrimidine(1245506-61-9)
• EPA Substance Registry System: 2-Chloro-5-methoxy-4-methylpyrimidine(1245506-61-9)

Safety Data

• Hazardous Substances Data: 1245506-61-9(Hazardous Substances Data)

Usage

General Description

2-Chloro-5-methoxy-4-methylpyrimidine is a chemical compound with the molecular formula C6H7ClN2O. It is a pyrimidine derivative with a chlorine atom at the 2 position, a methoxy group at the 5 position, and a methyl group at the 4 position. 2-Chloro-5-methoxy-4-methylpyrimidine is used as an intermediate in the production of pharmaceuticals and agrochemicals. It is also used in organic synthesis to introduce the 2-chloro-5-methoxy-4-methylpyrimidine moiety into various molecules. Additionally, it has been studied for its potential biological activities, such as anti-cancer and anti-inflammatory properties.

Upstream product

• 676-58-4 methylmagnesium chloride 
• 19646-07-2 2,4-dichloro-5-methoxypyrimidine 
• 75-16-1 methylmagnesium bromide 
• 823-96-1 Trimethylboroxine 

Downstream Products

• 1245506-62-0 2-chloro-4-methylpyrimidin-5-ol 
• 1369766-63-1 5-Benzyloxy-2-ethyl-4-methylpyrimidine 
• 1454928-76-7 4-(bromomethyl)-2-chloro-5-methoxypyrimidine 
• 1351345-55-5 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351338-59-4 (3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-54-4 ((3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-57-2 (3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-ylamine p-toluenesulfonate 

Relevant articles and documents

Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is becoming the most predominant burden of chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can develop into cirrhosis and hepatocellular cancer. Unfortunately, current options for therapeutic treatment of NASH are very limited. Among multiple pathways in NASH, farnesoid X receptor (FXR), a nuclear bile acid receptor, is well-recognized as an important effective target. Here we report the synthesis and characterization of compound HEC96719 a novel tricyclic FXR agonist based on a prior high-affinity nonsteroidal molecule GW4064. HEC96719 exhibits excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation. It also shows higher FXR selectivity and more favorable tissue distribution dominantly in liver and intestine. Preclinical data on pharmacokinetic properties, efficacy, and safety profiles overall indicate that HEC96719 is a promising drug candidate for NASH treatment.

CYCLOHEXYL ACID PYRAZOLE AZINES AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS

The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.